Ozanimod produces favorable long-term cardiac safety profile in UC, MS

SAN DIEGO — Minimal long-term cardiac safety findings were reported with ozanimod treatment in patients with ulcerative colitis and relapsing multiple sclerosis, according to research presented at Digestive Disease Week 2022.“Ozanimod is a newly approved, oral sphingosine-1-phosphate (S1P) receptor modulator that specifically targets S1P1 and S1P5 and prevents lymphocyte migration to the intestines. It’s approved in the U.S. and in Europe for the treatment of moderately to severely active UC as well as relapsing multiple sclerosis,” Millie Dascomb Long, MD, MPH, of theRead More